Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease.    The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology and offer potential differentiation from existing amyloid beta targeted agents.  […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!